Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery

Estimation with Quadratic Loss

James, W., & Stein, C. M. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-0919-5_30 · Cited by 2,319 · see citing works

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

Evans, S., WALLER, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,808 · see citing works

A Bayesian neural network method for adverse drug reaction signal generation

Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & Freitas, R. M. D. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,492 · see citing works

Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System

DuMouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 883 · see citing works

Selecting the right interestingness measure for association patterns

Tan, P., Kumar, V., & Srivastava, J. (2002) · ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/775047.775053 · Cited by 868 · see citing works

CONCEPTS OF INTERACTION

ROTHMAN, K. J., GREENLAND, S., & WALKER, A. M. (1980) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113015 · Cited by 851 · cited 1× · see citing works

Large-Scale Bayesian Logistic Regression for Text Categorization

Genkin, A., Lewis, D. D., & Madigan, D. (2007) · Technometrics · doi:10.1198/004017007000000245 · Cited by 812 · see citing works

VigiBase, the WHO Global ICSR Database System: Basic Facts

Lindquist, M. (2008) · Drug Information Journal · doi:10.1177/009286150804200501 · Cited by 599 · see citing works

Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis

Sanz, E. J., Cuevas, C. D. L., Kiuru, A., Bate, A., & Edwards, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17865-9 · Cited by 379 · see citing works

Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability:

F., D. D., & Neyman, J. (1957) · Journal of the American Statistical Association · doi:10.2307/2280857 · Cited by 351 · see citing works

Statistical significance tests.

Cox, D. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01987.x · Cited by 335 · see citing works

Empirical bayes screening for multi-item associations

DuMouchel, W., & Pregibon, D. (2001) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/502512.502526 · Cited by 268 · see citing works

Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events

Norén, G. N., Bate, A., Orre, R., & Edwards, I. R. (2005) · Statistics in Medicine · doi:10.1002/sim.2473 · Cited by 208 · see citing works

Discovering significant patterns

Webb, G. I. (2008) · Machine Learning · doi:10.1007/s10994-008-5045-y · Cited by 203 · see citing works

Discovering Significant Patterns

Webb, G. I. (2007) · Machine Learning · doi:10.1007/s10994-007-5006-x · Cited by 203 · see citing works

A statistical methodology for drug–drug interaction surveillance

Norén, G. N., Sundberg, R., Bate, A., & Edwards, I. R. (2008) · Statistics in Medicine · doi:10.1002/sim.3247 · Cited by 202 · see citing works

Temporal pattern discovery in longitudinal electronic patient records

Norén, G. N., Hopstadius, J., Bate, A., Star, K., & Edwards, I. R. (2009) · Data Mining and Knowledge Discovery · doi:10.1007/s10618-009-0152-3 · Cited by 170 · see citing works

Duplicate detection in adverse drug reaction surveillance

Norén, G. N., Orre, R., Bate, A., & Edwards, I. R. (2007) · Data Mining and Knowledge Discovery · doi:10.1007/s10618-006-0052-8 · Cited by 142 · see citing works

Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis

Sanz, E. J., DELASCUEVAS, C., KIURU, A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70271-3 · Cited by 81 · see citing works

Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database

Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2010) · Statistical Analysis and Data Mining The ASA Data Science Journal · doi:10.1002/sam.10078 · Cited by 67 · see citing works

Impact of Stratification on Adverse Drug Reaction Surveillance

Hopstadius, J., Norén, G. N., Bate, A., & Edwards, I. R. (2008) · Drug Safety · doi:10.2165/00002018-200831110-00008 · Cited by 59 · see citing works

Pharmacovigilance Data Mining With Methods Based on False Discovery Rates: A Comparative Simulation Study

Ahmed, I., Thiessard, F., Miremont‐Salamé, G., Bégaud, B., & Tubert‐Bitter, P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.111 · Cited by 46 · see citing works

Pattern Discovery and Detection: A Unified Statistical Methodology

Hand, D. J., & Bolton, R. J. (2004) · Journal of Applied Statistics · doi:10.1080/0266476042000270518 · Cited by 24 · see citing works

Accounting for Multiplicity in the Evaluation of “Signals” Obtained by Data Mining from Spontaneous Report Adverse Event Databases

Gould, A. L. (2006) · Biometrical Journal · doi:10.1002/bimj.200610296 · Cited by 21 · see citing works

Data Mining in Pharmacovigilance

Hauben, M., Madigan, D., Hochberg, A. M., Reisinger, S. J., & O’Hara, D. J. (2007) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200721050-00001 · Cited by 5 · see citing works

Abacavir and increased risk of myocardial infarction

Edwards, R., Bate, A., & Lindquist, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61333-1 · Cited by 3 · see citing works

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271 · see citing works

Optimizing ACS NSQIP Modeling for Evaluation of Surgical Quality and Risk: Patient Risk Adjustment, Procedure Mix Adjustment, Shrinkage Adjustment, and Surgical Focus

Cohen, M. E., Ko, C. Y., Bilimoria, K. Y., Zhou, L., Huffman, K., Wang, X., Liu, Y., Kraemer, K., Meng, X., Merkow, R., et al. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.02.027 · Cited by 583 · see citing works

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun‐Vignes, B., Mammen, A. L., Moslehi, J. J., & Salem, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 368 · see citing works

Cardiovascular Toxicities Associated With Ibrutinib

Salem, J., Manouchehri, A., Bretagne, M., Lebrun‐Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck‐Brentano, C., Brown, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.056 · Cited by 269 · see citing works

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Xiao, L., Salem, J., Clauß, S., Hanley, A., Bapat, A. C., Hulsmans, M., Iwamoto, Y., Wojtkiewicz, G. R., Çetinbaş, M., Schloss, M. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049210 · Cited by 251 · see citing works

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224 · see citing works

vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues

Bergvall, T., Norén, G. N., & Lindquist, M. (2013) · Drug Safety · doi:10.1007/s40264-013-0131-x · Cited by 207 · see citing works

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Hoisnard, L., Lebrun‐Vignes, B., Maury, S., Mahévas, M., Karoui, K. E., Roy, L., Zarour, A., Michel, M., Cohen, J. L., Amiot, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10777-w · Cited by 192 · see citing works

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., & He, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0754-2 · Cited by 191 · see citing works

Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations

Caster, O., Aoki, Y., Gattepaille, L. M., & Grundmark, B. (2020) · Drug Safety · doi:10.1007/s40264-020-00911-w · Cited by 187 · see citing works

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 157 · see citing works

Good Signal Detection Practices: Evidence from IMI PROTECT

Wisniewski, A. F. Z., Bate, A., Cédric Bousquet, B., Brueckner, A., Candore, G., Juhlin, K., Maciá, M. A., Manlik, K., Quarcoo, N., Seabroke, S., et al. (2016) · Drug Safety · doi:10.1007/s40264-016-0405-1 · Cited by 152 · see citing works

Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases

Candore, G., Juhlin, K., Manlik, K., Thakrar, B. T., Quarcoo, N., Seabroke, S., Wisniewski, A. F. Z., & Slattery, J. (2015) · Drug Safety · doi:10.1007/s40264-015-0289-5 · Cited by 149 · see citing works

A Standardized Dataset of a Spontaneous Adverse Event Reporting System

Khaleel, M. A., Khan, A. H., Ghadzi, S. M. S., Adnan, A. S., & Abdallah, Q. (2022) · Healthcare · doi:10.3390/healthcare10030420 · Cited by 143 · see citing works

Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database

Nguyen, L. S., Cooper, L. T., Kerneis, M., Funck-Brentano, C., Silvain, J., Brechot, N., Hekimian, G., Ammirati, E., Ben M’Barek, B., Redheuil, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27631-8 · Cited by 136 · see citing works

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Davidson, L., van den Reek, J. M. P. A., Bruno, M., van Hunsel, F. P. A. M., Herings, R. M. C., Matzaraki, V., Boahen, C. K., Kumar, V., Groenewoud, H., van de Veerdonk, F. L., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100266 · Cited by 124 · see citing works

Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures

Ang, P. S., Chen, Z., Chan, C. L., & Tai, B. C. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167184 · Cited by 111 · see citing works

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database

Arnaud, L., Mertz, P., Gavand, P., Martin, T., Chasset, F., Tebacher‐Alt, M., Lambert, A., Müller, C., Sibilia, J., Lebrun‐Vignes, B., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214598 · Cited by 107 · see citing works

Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank

Caster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014) · Drug Safety · doi:10.1007/s40264-014-0204-5 · Cited by 106 · see citing works

Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study

Ali, A. K., Heran, B. S., & Etminan, M. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1612 · Cited by 97 · see citing works

Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®

Aldea‐Perona, A., García-Sáiz, M., & Sanz, E. J. (2015) · Drug Safety · doi:10.1007/s40264-015-0360-2 · Cited by 95 · see citing works

Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database

Zhu, J., Chen, G., He, Z., Zheng, Y., Gao, S., Li, J., Ling, Y., Yu, X., Qiu, K., & Wu, J. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100951 · Cited by 86 · see citing works

Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

Sarangdhar, M., Tabar, S., Schmidt, C., Kushwaha, A., Shah, K., Dahlquist, J., Jegga, A. G., & Aronow, B. J. (2016) · Nature Biotechnology · doi:10.1038/nbt.3623 · Cited by 84 · see citing works

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 85 · see citing works

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Waliany, S., Zhu, H., Wakelee, H. A., Padda, S. K., Das, M. S., Ramchandran, K. J., Myall, N. J., Chen, T., Witteles, R. M., & Neal, J. W. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.030 · Cited by 83 · see citing works

Valproic Acid and Fatalities in Children: A Review of Individual Case Safety Reports in VigiBase

Star, K., Edwards, I. R., & Choonara, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108970 · Cited by 78 · see citing works

Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries

Cuevas, C. D. L., Sanz, E. J., Ruan, C., & de León, J. (2021) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2021.07.004 · Cited by 65 · see citing works

Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project

Caster, O., Dietrich, J., Kürzinger, M., Lerch, M., Maskell, S. R., Norén, G. N., Tcherny‐Lessenot, S., Vroman, B., Wisniewski, A. F. Z., & van Stekelenborg, J. (2018) · Drug Safety · doi:10.1007/s40264-018-0699-2 · Cited by 64 · see citing works

Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase

Sandberg, L., Taavola, H., Aoki, Y., Chandler, R. E., & Norén, G. N. (2020) · Drug Safety · doi:10.1007/s40264-020-00957-w · Cited by 63 · see citing works

Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases

Seabroke, S., Candore, G., Juhlin, K., Quarcoo, N., Wisniewski, A. F. Z., Arani, R. B., Painter, J. L., Tregunno, P. M., Norén, G. N., & Slattery, J. (2016) · Drug Safety · doi:10.1007/s40264-015-0388-3 · Cited by 60 · see citing works

Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase

Bai, X., Lin, X., Zheng, K., Chen, X., Wu, X., Huang, Y., & Zhuang, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02355-9 · Cited by 61 · see citing works

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS

Chen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616505 · Cited by 59 · see citing works

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Fusaroli, M., Isgrò, V., Cutroneo, P. M., Ferrajolo, C., Cirillo, V., Bufalo, F. D., Raschi, E., Poluzzi, E., & Trifirò, G. (2022) · Drug Safety · doi:10.1007/s40264-022-01194-z · Cited by 59 · see citing works

A comparison of disproportionality analysis methods in national adverse drug reaction databases of China

Hou, Y., Ye, X., Gui-zhi, W., Cheng, G., Du, X., & He, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915938 · Cited by 57 · see citing works

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system

Zhao, B., Fu, Y., Cui, S., Chen, X., Liu, S., & Luo, L. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1333662 · Cited by 53 · see citing works

Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases

van Hunsel, F. P. A. M., van de Koppel, S., van Puijenbroek, E., & Kant, A. C. (2018) · Drug Safety · doi:10.1007/s40264-018-0664-0 · Cited by 48 · see citing works

Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports

Wakao, R., Taavola, H., Sandberg, L., Iwasa, E., Soejima, S., Chandler, R. E., & Norén, G. N. (2019) · Drug Safety · doi:10.1007/s40264-019-00861-y · Cited by 48 · see citing works

Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review

Coste, A., Wong, A. Y. S., Bokern, M. P., Bate, A., & Douglas, I. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5548 · Cited by 47 · see citing works

The evolving role of disproportionality analysis in pharmacovigilance

Fusaroli, M., Raschi, E., Poluzzi, E., & Hauben, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368817 · Cited by 47 · see citing works

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database

Gérard, A. O., Merino, D., Obberghen, E. K. V., Rocher, F., Destère, A., Lantéri‐Minet, M., & Drici, M. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01424-w · Cited by 45 · see citing works

Rhabdomyolysis Reported for Children and Adolescents Treated with Antipsychotic Medicines: A Case Series Analysis

Star, K., Iessa, N., Almandil, N. B., Wilton, L., Curran, S. R., Edwards, I. R., & Wong, I. C. K. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0134 · Cited by 44 · see citing works

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Goldman, A., Fishman, B., Twig, G., Raschi, E., Cukierman‐Yaffe, T., Moshkovits, Y., Pomerantz, A., Ben‐Zvi, I., Dankner, R. S., & Maor, E. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01743-5 · Cited by 42 · see citing works

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS

Zhou, X., Ye, X., Guo, X., Liu, D., Xu, J., Hu, F., Zhai, Y., Gao, Y., Xu, X., Dong, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.766125 · Cited by 43 · see citing works

Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001 – 2012

Ferrajolo, C., Capuano, A., Trifirò, G., Moretti, U., Rossi, F., & Santuccio, C. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.939581 · Cited by 41 · see citing works

Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions

Cherkas, Y., Ide, J., & van Stekelenborg, J. (2022) · Drug Safety · doi:10.1007/s40264-022-01163-6 · Cited by 40 · see citing works

Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System

Norén, G. N., Bergvall, T., Ryan, P. B., Juhlin, K., Schuemie, M. J., & Madigan, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0095-x · Cited by 39 · see citing works

Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance

Norén, G. N., Caster, O., Juhlin, K., & Lindquist, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0198-z · Cited by 40 · see citing works

The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations

Vaughn, S., Strawn, J., Poweleit, E., Sarangdhar, M., & Ramsey, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070615 · Cited by 40 · see citing works

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Cao, Y., Lin, Z., Zhou, X., Guo, Z., & He, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.735466 · Cited by 40 · see citing works

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Jung, S. Y., Kim, M. S., Li, H. J., Lee, K. H., Koyanagi, A., Solmi, M., Kronbichler, A., Dragioti, E., Tizaoui, K., Cargnin, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13168 · Cited by 39 · see citing works

Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®

Pokladníková, J., Meyboom, R. H. B., Meincke, R., Niedrig, D., & Russmann, S. (2016) · Drug Safety · doi:10.1007/s40264-016-0401-5 · Cited by 38 · see citing works

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study

Hilmi, M., Éderhy, S., Waintraub, X., Funck‐Brentano, C., Cohen, A. A., Vozy, A., Lebrun‐Vignes, B., Moslehi, J. J., Nguyen, L. S., & Salem, J. (2020) · Pharmaceuticals · doi:10.3390/ph13100325 · Cited by 38 · see citing works

Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase

Bai, X., Chen, X., Wu, X., Huang, Y., Zhuang, Y., & Lin, X. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0535 · Cited by 37 · see citing works

Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

Bai, X., Chen, X., Wu, X., Huang, Y., Zhuang, Y., Chen, Y., Feng, C., & Lin, X. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01226-4 · Cited by 37 · see citing works

Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study

Goldman, A., Raschi, E., Cukierman‐Yaffe, T., Dankner, R. S., Shouval, R., Shechter, M., Ben‐Zvi, I., Gerstein, H. C., & Maor, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab209 · Cited by 37 · see citing works

Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System

Dong, Z., Ye, X., Chen, C., Wang, R., Liu, D., Xu, X., Zhou, X., & He, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15361 · Cited by 37 · see citing works

Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase

Cuevas, C. D. L., Sanz, E. J., Rohde, C., & de León, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2032659 · Cited by 35 · see citing works

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II

de León, J., Baldessarini, R. J., Balon, R., Bilbily, J., Caroff, S. N., Citrome, L., Correll, C. U., Cotes, R. O., Davis, J. M., DeLisi, L. E., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001990 · Cited by 35 · see citing works

Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems

Gosho, M., Maruo, K., Tada, K., & Hirakawa, A. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2233-3 · Cited by 34 · see citing works

vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real‐world use

Caster, O., Sandberg, L., Bergvall, T., Watson, S., & Norén, G. N. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4247 · Cited by 34 · see citing works

Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS

Chen, Y., Fan, Q., Liu, Y., Shi, Y., & Luo, H. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115300 · Cited by 34 · see citing works

Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases

DuMouchel, W., Ryan, P. B., Schuemie, M. J., & Madigan, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0106-y · Cited by 34 · see citing works

Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database

Xia, S., Gong, H., Zhao, Y., Guo, L., Wang, Y., Ma, R., Zhang, B., Sarangdhar, M., Noguchi, Y., & Yan, M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2920 · Cited by 33 · see citing works

An evaluation of statistical approaches to postmarketing surveillance

Ding, Y., Markatou, M., & Ball, R. (2020) · Statistics in Medicine · doi:10.1002/sim.8447 · Cited by 33 · see citing works

Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study

Dolladille, C., Éderhy, S., Ezine, E., Choquet, S., Nguyen, L. S., Alexandre, J., Moslehi, J. J., Dechartres, A., & Salem, J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26259 · Cited by 33 · see citing works

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database

Zhou, J., Wei, Z., Xu, B., Liu, M., Xu, R., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1039867 · Cited by 32 · see citing works

Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

Goldman, A., Bomze, D., Dankner, R. S., Fourey, D., Boursi, B., Arad, M., & Maor, E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00817-2 · Cited by 32 · see citing works

Outlier removal to uncover patterns in adverse drug reaction surveillance – a simple unmasking strategy

Juhlin, K., Ye, X., Star, K., & Norén, G. N. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3474 · Cited by 32 · see citing works

Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review

Jozwiak, M., Géri, G., Laghlam, D., Boussion, K., Dolladille, C., & Nguyen, L. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.826446 · Cited by 31 · see citing works

Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer

Waliany, S., Caswell-Jin, J. L., Riaz, F., Myall, N. J., Zhu, H., Witteles, R. M., & Neal, J. W. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.007 · Cited by 33 · see citing works

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis

Hlavaty, A., Roustit, M., Montani, D., Chaumais, M., Guignabert, C., Humbert, M. J. C., Cracowski, J., & Khouri, C. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15436 · Cited by 30 · see citing works

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy

Song, Z., Tu, D.-Y., Tang, G., Liu, N., Tai, Z.-G., Yang, J.-M., & Wang, Y. (2023) · Haematologica · doi:10.3324/haematol.2022.281455 · Cited by 22 · see citing works

Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre

Star, K., Sandberg, L., Bergvall, T., Choonara, I., Caduff‐Janosa, P., & Edwards, I. R. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4734 · Cited by 29 · see citing works

Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study

Fusaroli, M., Giunchi, V., Battini, V., Gringeri, M., Rimondini, R., Menchetti, M., Radice, S., Pozzi, M., Nobile, M., Clementi, E., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13511 · Cited by 29 · see citing works

A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies

Pacaci, A., Gönül, S., Sınacı, A. A., Yüksel, M., & Ertürkmen, G. B. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00435 · Cited by 29 · see citing works

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system

Wang, F., Qi, W., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986357 · Cited by 28 · see citing works

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database

Anquetil, C., Salem, J., Lebrun‐Vignes, B., Touhami, S., Desbois, A. C., Maalouf, G., Domont, F., Allenbach, Y., Cacoub, P., Bodaghi, B., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102454 · Cited by 28 · see citing works

Robust discovery of local patterns

Hopstadius, J., & Norén, G. N. (2012) · International Health Informatics Symposium · doi:10.1145/2110363.2110395 · Cited by 28 · see citing works

Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database

Wang, Q., Liu, J., Sun, H., Dong, Y., Tan, W., Tang, Z., & Jiang, Y. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2250720 · Cited by 27 · see citing works

Sex differences in adverse drug reactions: Are women more impacted?

Lacroix, C., Maurier, A., Largeau, B., Destère, A., Thillard, E.-M., Drici, M., Micallef, J., & Jonville‐Béra, A. ‐. (2022) · Therapies · doi:10.1016/j.therap.2022.10.002 · Cited by 27 · see citing works

Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities

Spetz, J. K. E., Florido, M. H. C., Fraser, C. S., Qin, X., Choiniere, J., Yu, S. J., Singh, R., Friesen, M., Rubin, L. L., Salem, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6579 · Cited by 26 · see citing works

Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

de León, J., Ruan, C., Schoretsanitis, G., Tezanos, A. G. V., Spina, E., Sanz, E. J., Betancort, M., & Cuevas, C. D. L. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2373111 · Cited by 26 · see citing works

Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS

He, L., Yu, Y., Wei, Y., Huang, J., Shen, Y., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.815151 · Cited by 26 · see citing works

Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study

Balcerac, A., Bihan, K., Psimaras, D., Lebrun‐Vignes, B., Salem, J., & Weiss, N. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11450-y · Cited by 26 · see citing works

Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database

Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., & Wu, X. (2024) · Endocrine · doi:10.1007/s12020-024-04112-8 · Cited by 25 · see citing works

Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021

Wang, Y., Cui, C., Ren, X., Dong, X., & Cui, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.988013 · Cited by 25 · see citing works

Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study

Rodríguez, A. J., Nerlekar, N., & Ebeling, P. R. (2022) · Bone · doi:10.1016/j.bone.2022.116647 · Cited by 24 · see citing works

Charting and Sidestepping the Pitfalls of Disproportionality Analysis

Fusaroli, M., Sartori, D., van Puijenbroek, E., & Norén, G. N. (2025) · Drug Safety · doi:10.1007/s40264-025-01604-y · Cited by 31 · see citing works

Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors

Yang, K., Li, J., Sun, Z., Bai, C., & Zhao, L. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01055-8 · Cited by 25 · see citing works

The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System

Zhou, J., Wei, Z., Lai, W., Liu, M., & Wu, X. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16354 · Cited by 23 · see citing works

VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines

Brand, J. S., Gauffin, O., Sartori, D., Fusaroli, M., Sköld, H., Bergvall, T., Sandberg, L., Wallberg, M., Hjelmström, P., & Norén, G. N. (2026) · Drug Safety · doi:10.1007/s40264-025-01642-6 · Cited by 23 · see citing works

Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database

Balcerac, A., Bihan, K., Lebrun‐Vignes, B., Thabut, D., Salem, J., & Weiss, N. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01026-4 · Cited by 23 · see citing works

Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)

Gómez-Lumbreras, A., Boyce, R. D., Zapata, L. V., Tan, M. S., Hansten, P. D., Horn, J. R., & Malone, D. C. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221148031 · Cited by 23 · see citing works

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022

Wang, Y., Cui, C., Deng, L., Wang, L., & Ren, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127128 · Cited by 23 · see citing works

Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study

Gauffin, O., Brand, J. S., Vidlin, S. H., Sartori, D., Asikainen, S., Català, M., Chalabi, E., Dedman, D., Danilović, A., Duarte‐Salles, T., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01353-w · Cited by 23 · see citing works

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database

Hu, F., Zhai, Y., Yuan, L., Liang, J., Xu, J., Guo, X., Zhou, X., Lin, Z., Jin-hai, S., Ye, X., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4343 · Cited by 23 · see citing works

An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021

Li, X., Ndungu, P., Taneja, S. B., Chapin, M. R., Egbert, S., Akenapalli, K., Paine, M. F., Kane‐Gill, S. L., & Boyce, R. D. (2023) · Clinical and Translational Science · doi:10.1111/cts.13505 · Cited by 22 · see citing works

Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

Cuevas, C. D. L., Sanz, E. J., & de León, J. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s495254 · Cited by 22 · see citing works

CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis

Régnier, P., Joncour, A. L., Maciejewski‐Duval, A., Darrasse-Jèze, G., Dolladille, C., Meijers, W. C., Bastarache, L. A., Fouret, P. J., Bruneval, P., Arbaretaz, F., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.322330 · Cited by 22 · see citing works

Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites

Juhlin, K., Karimi, G., Andér, M., Camilli, S., Dheda, M., Tan, S. H., Isahak, R., Lee, S. J., Vaughan, S. M., Caduff‐Janosa, P., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0271-2 · Cited by 22 · see citing works

Temporal pattern discovery for trends and transient effects

Norén, G. N., Bate, A., Hopstadius, J., Star, K., & Edwards, I. R. (2008) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/1401890.1402005 · Cited by 47 · see citing works

Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database

CasterOla, Niklas, N., MadiganDavid, & BateAndrew (2010) · Statistical Analysis and Data Mining The ASA Data Science Journal · doi:10.5555/1855228.1855230

Temporal pattern discovery in longitudinal electronic patient records

Norén, G. N., Hopstadius, J., Bate, A., Star, K., & Edwards, I. R. (2009) · Data Mining and Knowledge Discovery · doi:10.1007/s10618-009-0152-3 · Cited by 170 · see citing works

Efficient discovery of risk patterns in medical data

Li, J., Fu, A. W.-C., & Fahey, P. P. (2008) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2008.07.008 · Cited by 54 · see citing works

Significance of Patterns in Data Visualisations

Savvides, R., Henelius, A., Oikarinen, E., & Puolamäki, K. (2019) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/3292500.3330994 · Cited by 10 · see citing works